ATE56364T1 - Lebender gereinigter impfstoff gegen die marek'sche krankheit. - Google Patents

Lebender gereinigter impfstoff gegen die marek'sche krankheit.

Info

Publication number
ATE56364T1
ATE56364T1 AT85200461T AT85200461T ATE56364T1 AT E56364 T1 ATE56364 T1 AT E56364T1 AT 85200461 T AT85200461 T AT 85200461T AT 85200461 T AT85200461 T AT 85200461T AT E56364 T1 ATE56364 T1 AT E56364T1
Authority
AT
Austria
Prior art keywords
disease
marek
virus
mdv
monovalent
Prior art date
Application number
AT85200461T
Other languages
English (en)
Inventor
Boer Gerben Foppe De
Original Assignee
Centraal Diergeneeskundig Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centraal Diergeneeskundig Inst filed Critical Centraal Diergeneeskundig Inst
Application granted granted Critical
Publication of ATE56364T1 publication Critical patent/ATE56364T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/816—Viral vaccine for avian species, e.g. poultry or other birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT85200461T 1984-04-09 1985-03-25 Lebender gereinigter impfstoff gegen die marek'sche krankheit. ATE56364T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL8401120A NL8401120A (nl) 1984-04-09 1984-04-09 Viruspreparaat, waarmee gevaccineerd kan worden tegen de ziekte van marek.
EP85200461A EP0159743B1 (de) 1984-04-09 1985-03-25 Lebender gereinigter Impfstoff gegen die Marek'sche Krankheit

Publications (1)

Publication Number Publication Date
ATE56364T1 true ATE56364T1 (de) 1990-09-15

Family

ID=19843774

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85200461T ATE56364T1 (de) 1984-04-09 1985-03-25 Lebender gereinigter impfstoff gegen die marek'sche krankheit.

Country Status (17)

Country Link
US (1) US4673572A (de)
EP (1) EP0159743B1 (de)
JP (1) JPS6123A (de)
AT (1) ATE56364T1 (de)
AU (1) AU574164B2 (de)
CA (1) CA1251397A (de)
DD (1) DD232822A5 (de)
DE (1) DE3579617D1 (de)
ES (1) ES8605680A1 (de)
HU (1) HU194496B (de)
IL (1) IL74809A (de)
IN (1) IN163229B (de)
MX (1) MX7718E (de)
NL (1) NL8401120A (de)
WO (1) WO1985004588A1 (de)
YU (1) YU44687B (de)
ZA (1) ZA852564B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456101A (en) * 1980-11-08 1984-06-26 Honda Giken Kogyo Kabushiki Kaisha Vehicular brake operating system
JP2508625B2 (ja) * 1985-08-30 1996-06-19 ソニー株式会社 半導体レ−ザ−
FR2598596B1 (fr) * 1986-05-15 1990-10-19 Sanofi Elf Bio Ind Procede de traitement du lait en vue de l'obtention de fromages
US5849299A (en) * 1991-06-28 1998-12-15 The United States Of America As Represented By The Secretary Of Agriculture Attenuated revertant serotype 1 marek's disease vaccine
WO1993023078A1 (en) * 1992-05-19 1993-11-25 Viktoria Alexeevna Lukina Vaccine for prophylaxis of marek disease of birds and method of its preparation
IL114501A (en) * 1994-07-14 1999-08-17 Akzo Nobel Nv Marek's disease virus vaccine
EP0703294A1 (de) * 1994-07-14 1996-03-27 Akzo Nobel N.V. Virusimpfstoff gegen Mareksche Krankheit
EP0748867A1 (de) * 1995-06-12 1996-12-18 Duphar International Research B.V Marek-Krankheit Vakzine
US5989805A (en) * 1995-10-27 1999-11-23 Board Of Trustees Operating Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines
CA2257409A1 (en) * 1996-06-04 1997-12-11 University Of Georgia Research Foundation, Inc. Modified live avian polyomavirus vaccine in psittacine birds
EP1038952A3 (de) * 1998-12-09 2001-06-27 Pfizer Products Inc. Verfahren zur Herstellung von Mareks Disease Virus (MDV) unter Verwendung von kontinuierlichen Vogelzellinien
EA030866B1 (ru) 2012-03-22 2018-10-31 Мериал, Инк. Модифицированный вирус болезни марека и вакцины на его основе

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1292803A (en) * 1968-11-18 1972-10-11 Nat Res Dev Improvements relating to the production of antigens
US3642574A (en) * 1970-04-29 1972-02-15 Us Agriculture Method for producing vaccine for immunization of poultry against marek{3 s disease
US3783098A (en) * 1971-08-10 1974-01-01 Cornell Res Foundation Inc Highly potent,viable and stable cellfree virus preparations from cells infected with cell-associated viruses and method for obtaining the same
US4160024A (en) * 1978-05-01 1979-07-03 Cornell Research Foundation, Inc. Marek's disease vaccine

Also Published As

Publication number Publication date
NL8401120A (nl) 1985-11-01
YU59985A (en) 1988-06-30
ZA852564B (en) 1985-11-27
ES541930A0 (es) 1986-04-16
DD232822A5 (de) 1986-02-12
AU574164B2 (en) 1988-06-30
AU4156185A (en) 1985-11-01
EP0159743B1 (de) 1990-09-12
IN163229B (de) 1988-08-27
DE3579617D1 (de) 1990-10-18
WO1985004588A1 (en) 1985-10-24
ES8605680A1 (es) 1986-04-16
JPH0317808B2 (de) 1991-03-11
EP0159743A1 (de) 1985-10-30
CA1251397A (en) 1989-03-21
YU44687B (en) 1990-12-31
IL74809A0 (en) 1985-07-31
HUT38542A (en) 1986-06-30
US4673572A (en) 1987-06-16
JPS6123A (ja) 1986-01-06
MX7718E (es) 1990-10-10
HU194496B (en) 1988-02-29
IL74809A (en) 1990-09-17

Similar Documents

Publication Publication Date Title
ATE56364T1 (de) Lebender gereinigter impfstoff gegen die marek'sche krankheit.
EP0125245B1 (de) Kultivierung von hämorrhagische enteritis hervorrufenden viren in truthahn-gewebe-zellkulturen
Roos et al. Characterization of a cell culture persistently infected with the DA strain of Theiler's murine encephalomyelitis virus
ALLEN et al. Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity
MXPA01005808A (es) Cepa de virus de enfermedad bursal infecciosa para administracion en huevo.
CA2222482A1 (en) Non-virulent mycoplasma synoviae and vaccine thereof
CA2058386A1 (en) Cell free marek's disease virus vaccine
Wiebe et al. Virion envelope glycoproteins as epidermiological markers of Venezuelan encephalitis virus isolates
Carmichael et al. Small-plaque variant of canine herpesvirus with reduced pathogenicity for newborn pups
US4213965A (en) Small-plaque variant canine herpesvirus vaccine
Eisenstein et al. Salmonella vaccines: Protection by endotoxin protein and lipopolysaccharide in two different mouse strains.
JPS5756430A (en) Live virus vaccine for canine parainfluenza
US5565202A (en) Low enhancement serotype 2 vaccine for marek's disease
Takayama et al. Comparative restriction endonuclease analysis of varicella-zoster virus clinical isolates
JP3040157B2 (ja) イヌパルボウイルス（ｃｐｖ）を含む弱毒イヌパルボウイルスワクチンとイヌ科動物におけるｃｐｖ感染予防
CA1289881C (en) Vaccine against herpes simplex
ES2074965A1 (es) Virus mutante recombinante de rinotraqueitis infecciosa bovina y vacunas que lo contienen.
KR960016906A (ko) 약독화 수두 생바이러스 백신 및 그의 제조방법
Allison Tumour Viruses: Are Observations on Tumour Viruses in Animals Applicable to Man?
EP1161953A3 (de) IBDV Stamm für in ovo Verabreichung
岡崎和子 et al. The immunodominant glycoprotein complex of equid herpesvirus 1 (EHV-1) and the counterpart of EHV-4.
SU1707075A1 (ru) Штамм вируса болезни Марека дл изготовлени вакцины против болезни Марека
Fleury et al. Comparison of the structural polypeptides of the american and african strains of Paramyxovirus Yucaipa
Lung et al. Natural Epstein-Barr Virus Isolates from Southern China and California Differ in the Bam Hl I Region
RO96364B1 (ro) PROCEDEU DE PREPARARE A UNUI VACCIN VIU PURIFICAT îMPOTRIVA BOLII LUI MAREK

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee